Impact of pre-existing comorbidities on outcomes of patients undergoing surgical aortic valve replacement - rationale and design of the international IMPACT registry.
Aged
Aged, 80 and over
Aortic Valve
/ surgery
Aortic Valve Stenosis
/ surgery
Bioprosthesis
Comorbidity
Coronary Artery Bypass
Female
Germany
Heart Valve Prosthesis
Heart Valve Prosthesis Implantation
Hemodynamics
Humans
Inflammation
Male
Middle Aged
Prospective Studies
Registries
Research Design
Transcatheter Aortic Valve Replacement
Treatment Outcome
Aortic valve disease
Comorbidities
Real-world setting
SAVR
Surgical aortic valve replacement
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
25 Mar 2021
25 Mar 2021
Historique:
received:
06
11
2020
accepted:
16
03
2021
entrez:
26
3
2021
pubmed:
27
3
2021
medline:
16
6
2021
Statut:
epublish
Résumé
Degenerative aortic valve disease accounts for 10-20% of all cardiac surgical procedures. The impact of pre-existing comorbidities on the outcome of patients undergoing surgical aortic valve replacement (SAVR) needs further research. The IMPACT registry is a non-interventional, prospective, open-label, multicenter, international registry with a follow-up of 5 years to assess the impact of pre-existing comorbidities of patients undergoing SAVR with the INSPIRIS RESILIA aortic valve on outcomes. IMPACT will be conducted across 25 sites in Austria, Germany, The Netherlands and Switzerland and intends to enroll approximately 500 patients. Patients will be included if they are at least 18 years of age and are scheduled to undergo SAVR with the INSPIRIS RESILIA Aortic Valve with or without concomitant ascending aortic root replacement and/or coronary bypass surgery. The primary objective is to determine all-cause mortality at 1, 3, and 5 years post SAVR. Secondary objectives include cardiac-related and valve-related mortality and structural valve deterioration including hemodynamics and durability, valve performance and further clinical outcomes in the overall study population and in specific patient subgroups characterized by the presence of chronic kidney disease, hypertension, metabolic syndrome and/or chronic inflammation. IMPACT is a prospective, multicenter European registry, which will provide much-needed data on the impact of pre-existing comorbidities on patient outcomes and prosthetic valve performance, and in particular the performance of the INSPIRIS RESILIA, in a real-world setting. The findings of this study may help to support and expand appropriate patient selection for treatment with bioprostheses. ClinicalTrials.gov identifier: NCT04053088 .
Sections du résumé
BACKGROUND
BACKGROUND
Degenerative aortic valve disease accounts for 10-20% of all cardiac surgical procedures. The impact of pre-existing comorbidities on the outcome of patients undergoing surgical aortic valve replacement (SAVR) needs further research.
METHODS
METHODS
The IMPACT registry is a non-interventional, prospective, open-label, multicenter, international registry with a follow-up of 5 years to assess the impact of pre-existing comorbidities of patients undergoing SAVR with the INSPIRIS RESILIA aortic valve on outcomes. IMPACT will be conducted across 25 sites in Austria, Germany, The Netherlands and Switzerland and intends to enroll approximately 500 patients. Patients will be included if they are at least 18 years of age and are scheduled to undergo SAVR with the INSPIRIS RESILIA Aortic Valve with or without concomitant ascending aortic root replacement and/or coronary bypass surgery. The primary objective is to determine all-cause mortality at 1, 3, and 5 years post SAVR. Secondary objectives include cardiac-related and valve-related mortality and structural valve deterioration including hemodynamics and durability, valve performance and further clinical outcomes in the overall study population and in specific patient subgroups characterized by the presence of chronic kidney disease, hypertension, metabolic syndrome and/or chronic inflammation.
DISCUSSION
CONCLUSIONS
IMPACT is a prospective, multicenter European registry, which will provide much-needed data on the impact of pre-existing comorbidities on patient outcomes and prosthetic valve performance, and in particular the performance of the INSPIRIS RESILIA, in a real-world setting. The findings of this study may help to support and expand appropriate patient selection for treatment with bioprostheses.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov identifier: NCT04053088 .
Identifiants
pubmed: 33766089
doi: 10.1186/s13019-021-01434-w
pii: 10.1186/s13019-021-01434-w
pmc: PMC7993500
doi:
Banques de données
ClinicalTrials.gov
['NCT04053088']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
51Subventions
Organisme : Edwards Lifesciences
ID : n.a.
Références
Glob Health Action. 2008 Dec 16;1:
pubmed: 20027239
Arch Surg. 2002 Apr;137(4):428-32; discussion 432-3
pubmed: 11926947
Eur J Cardiothorac Surg. 2017 Sep 1;52(3):408-417
pubmed: 28874031
Clin Med Insights Cardiol. 2012;6:125-39
pubmed: 22952419
Mayo Clin Proc. 2010 May;85(5):483-500
pubmed: 20435842
Open Heart. 2018 Apr 21;5(1):e000756
pubmed: 29713484
Circulation. 2006 Jul 4;114(1 Suppl):I512-7
pubmed: 16820629
J Am Coll Cardiol. 2007 Sep 25;50(13):1205-13
pubmed: 17888836
J Thorac Dis. 2019 Jun;11(6):2340-2349
pubmed: 31372271
Circulation. 2018 Jan 23;137(4):388-399
pubmed: 29358344
Ann Thorac Surg. 2008 Apr;85(4):1490-5
pubmed: 18355567
Int J Qual Health Care. 1998 Apr;10(2):113-23
pubmed: 9690884
Ann Thorac Surg. 2011 Jun;91(6):1798-806; discussion 1806-7
pubmed: 21536247
Crit Rev Oncol Hematol. 2008 Aug;67(2):124-32
pubmed: 18375141
EuroIntervention. 2017 Sep 20;13(7):804-810
pubmed: 28437243
J Am Heart Assoc. 2019 Feb 5;8(3):e009980
pubmed: 30686093
Cardiovasc Diabetol. 2017 Nov 09;16(1):144
pubmed: 29121921
F1000Res. 2019 Jul 22;8:
pubmed: 31354937
World J Orthop. 2015 Apr 18;6(3):331-9
pubmed: 25893176
BMJ. 2016 Sep 28;354:i5065
pubmed: 27683072
J Thorac Cardiovasc Surg. 2015 Jan;149(1):340-5
pubmed: 25439467
Ann Thorac Surg. 2013 Apr;95(4):1491-505
pubmed: 23291103
Anaesthesia. 2020 Jan;75 Suppl 1:e143-e150
pubmed: 31903564
Thorac Cardiovasc Surg. 1995 Feb;43(1):19-26
pubmed: 7540324
Interact Cardiovasc Thorac Surg. 2019 Sep 1;29(3):371-377
pubmed: 31220291
Eur J Cardiothorac Surg. 2017 Sep 1;52(3):432-439
pubmed: 28605428
J Cardiothorac Surg. 2020 May 27;15(1):119
pubmed: 32460798
Heart. 2018 Aug;104(16):1323-1332
pubmed: 29735584
Heart. 1997 Nov;78(5):472-4
pubmed: 9415006
Semin Oncol Nurs. 2017 Feb;33(1):80-86
pubmed: 28062326
J Card Surg. 2015 Aug;30(8):631-9
pubmed: 26108804